ArticleBio-protocol2026
Inverse Restriction Site-Associated DNA Sequencing (iRAD-seq).
Article in Bio-protocol, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reduced representation sequencing (RRS), particularly through restriction site-associated DNA sequencing (RAD-seq), has been widely adopted for whole-genome genotyping due to its cost-effectiveness and cross-species applicability. Nevertheless, conventional RAD-seq approaches are constrained by intricate workflows and substantial labor intensity. These methods predominantly adhere to a "fragment selection precedes library construction" paradigm, wherein DNA fragments adjacent to restriction enzyme cleavage sites are specifically targeted. In contrast, we present an innovative strategy termed inverse restriction site-associated DNA sequencing (iRAD-seq), which implements a reversed workflow, "library construction precedes fragment selection," to enable efficient enrichment of DNA fragments not associated with restriction sites for genome-wide genotyping. This approach harnesses Tn5 transposase to concurrently fragment genomic DNA and ligate sequencing adapters, followed by pooled processing of hundreds of libraries under a unified batch restriction digestion step. The iRAD-seq workflow thereby achieves significant simplification and enhances operational efficiency in RAD-seq library preparation. Key features • iRAD-seq is a swift and simple RRS method based on Tn5 library construction and restriction enzyme digestion. • The library preparation for iRAD-seq adopts a strategy of library construction followed by fragment selection. • iRAD-seq enables effective reduction of genome complexity, with the extent of simplification flexibly tunable by adjusting the combination of restriction enzymes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.